Sort   by:  
 Page size 
ProteomicsPhosphoproteomics of BYL719 (alpelisib)-Resistant T47D Human Breast Cancer Cell Line
The PI3Kalpha-specific inhibitor Alpelisib (BYL719) has been approved for the treatment of metastatic ER+/HER2- breast cancer patients in combination with Fulvestrant. After initial response, patients develop drug resistance and disease relapses. In order to identify signalling pathways contributing...
ORGANISM(S): Homo sapiens (Human) 
2023-12-05 | PXD033956 | Pride
Targeted therapies Human breast cancer Pi3k Byl719 Phosphoproteomics Alpelisib 
TranscriptomicsAXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Phosphoinositide-3-kinase (PI3K)-α inhibitors are clinically active in squamous carcinoma (SCC) of the head and neck (H&N) bearing mutations or amplification of PIK3CA. We aimed to identify potential mechanism of resistance and have observed that SCCs cells overcome the antitumor effects of the PI3K...
ORGANISM(S): Homo sapiens 
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
ClinicalStudy of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
2134540 | ecrin-mdr-crc
UnknownBYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Not available
S-EPMC10408073 | biostudies-literature
UnknownPI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Not available
S-EPMC7817006 | biostudies-literature
UnknownPreclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Not available
S-EPMC4473326 | biostudies-literature
UnknownThe selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Not available
S-EPMC5553670 | biostudies-literature
UnknownPopulation pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.
Not available
S-EPMC4243905 | biostudies-literature
UnknownHER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Not available
S-EPMC6591241 | biostudies-literature
UnknownA Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Not available
S-EPMC9478566 | biostudies-literature
Sort   by:  
 Page size